1. In Vivo
  2. >>Growth

Alzheimer's Disease: Defusing The Bomb By 2025

 
• By Lucie Ellis-Taitt

The number of drug candidates in development for Alzheimer's is at its highest-ever level and despite the lack of success to date, biopharma companies continue to believe the potential rewards are worth the risk. As R&D in the field accelerates, therapies that treat not only symptoms of the disease but also slow its progression are expected to arrive sooner rather than later.

"This is a time bomb." These words could refer to any number of perilous global issues currently grabbing headlines. We could be talking about global warming, China's economic downturn, fossil fuels, Ebola or terrorism – but we're not. These are the words used by Gill Morgan, chair of NHS Providers, the UK's National Health Service trade association for acute, ambulance, community and mental health services, to describe Alzheimer's disease.

Alzheimer's disease, an irreversible, progressive neurodegenerative disease, is the most common cause of dementia among the elderly, accounting for between...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

Financing Quarterly Statistics, Q2 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By Ashley Yeo

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

More from In Vivo

Podcast: Poolbeg CEO On The Biotech’s Big Bet On Small Molecules

 
• By Jo Shorthouse

In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company’s ambitious pipeline and strategic direction.

video
Sponsored by:

Meeting the demands of the global biologics market

Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG

Mapping The Power And Potential Of Europe’s Market Access Collaborations

 
• By Leela Barham

Understand who’s influencing access decisions and how pharma can engage strategically across the continent.